John R. Petrie

17.5k total citations · 3 hit papers
177 papers, 9.6k citations indexed

About

John R. Petrie is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, John R. Petrie has authored 177 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Endocrinology, Diabetes and Metabolism, 45 papers in Molecular Biology and 45 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in John R. Petrie's work include Diabetes Treatment and Management (48 papers), Diabetes Management and Research (41 papers) and Metabolism, Diabetes, and Cancer (40 papers). John R. Petrie is often cited by papers focused on Diabetes Treatment and Management (48 papers), Diabetes Management and Research (41 papers) and Metabolism, Diabetes, and Cancer (40 papers). John R. Petrie collaborates with scholars based in United Kingdom, United States and Italy. John R. Petrie's co-authors include John Connell, Naveed Sattar, Rhian M. Touyz, Tomasz J. Guzik, Helen M. Colhoun, Gwyn W. Gould, Henry L. Elliott, Stephen J. Cleland, Sarah H. Wild and Helen Lyall and has published in prestigious journals such as The Lancet, JAMA and Journal of Biological Chemistry.

In The Last Decade

John R. Petrie

170 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms

2017 1.2k citations John R. Petrie et al. profile →
Low Grade Chronic Inflammation in Women with Polycystic Ovarian Syndrome

2001 513 citations John R. Petrie, Naveed Sattar et al. profile →
Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010

2015 418 citations Shona Livingstone, Robert S. Lindsay et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John R. Petrie United Kingdom	53	4.7k	2.5k	1.9k	1.8k	1.4k	177	9.6k
Ian F. Godsland United Kingdom	52	4.3k 0.9×	2.0k 0.8×	1.4k 0.7×	1.5k 0.8×	1.5k 1.0×	176	9.3k
Kieren J. Mather United States	44	4.5k 1.0×	2.3k 0.9×	2.2k 1.2×	1.8k 1.0×	2.6k 1.8×	186	10.5k
Sophia Zoungas Australia	60	7.2k 1.5×	3.6k 1.5×	1.7k 0.9×	2.6k 1.5×	1.2k 0.9×	290	14.8k
Christian Berne Sweden	58	4.3k 0.9×	2.5k 1.0×	1.7k 0.9×	2.7k 1.5×	2.7k 1.9×	211	11.2k
Alexandra Kautzky‐Willer Austria	52	3.6k 0.8×	1.8k 0.7×	1.7k 0.9×	2.4k 1.3×	1.8k 1.3×	461	11.3k
Kwang Kon Koh South Korea	48	3.3k 0.7×	3.4k 1.4×	1.2k 0.7×	2.4k 1.4×	1.9k 1.3×	173	9.6k
Kåre I. Birkeland Norway	52	4.7k 1.0×	1.5k 0.6×	2.2k 1.2×	2.3k 1.3×	2.3k 1.6×	244	10.8k
Zachary T. Bloomgarden United States	44	5.9k 1.2×	1.3k 0.5×	2.1k 1.1×	2.2k 1.2×	1.1k 0.8×	264	9.5k
Alicia J. Jenkins Australia	61	5.0k 1.0×	1.9k 0.8×	2.8k 1.5×	2.3k 1.3×	1.7k 1.2×	420	14.4k
Tracey McLaughlin United States	43	3.1k 0.7×	2.0k 0.8×	1.5k 0.8×	1.6k 0.9×	3.7k 2.6×	113	9.3k

Countries citing papers authored by John R. Petrie

Since Specialization

Citations

This map shows the geographic impact of John R. Petrie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Petrie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Petrie more than expected).

Fields of papers citing papers by John R. Petrie

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John R. Petrie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Petrie. The network helps show where John R. Petrie may publish in the future.

Co-authorship network of co-authors of John R. Petrie

This figure shows the co-authorship network connecting the top 25 collaborators of John R. Petrie. A scholar is included among the top collaborators of John R. Petrie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John R. Petrie. John R. Petrie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hillier, Roxane J., et al.. (2025). Surgical capacity in ophthalmology: the unmet need for sustainable solutions. Eye. 40(4). 452–464.

Chiriacò, Martina, Domenico Tricò, John R. Petrie, et al.. (2025). Impact of overweight and obesity on fasting insulin secretion in men and women without diabetes: effect sizes and mechanisms. Diabetologia. 69(4). 1035–1048.

Salt, Ian P., et al.. (2025). Heterogeneous metabolic response of endothelial cells from different vascular beds to experimental hyperglycaemia and metformin. The Journal of Physiology. 1 indexed citations

Dowsett, Laura, et al.. (2024). RWOP2 Heterogeneous metabolic response of endothelial cells from different vascular beds to hyperglycaemia and metformin. A1.2–A1.

Fu, Edouard L., Stuart J. McGurnaghan, Bryan R. Conway, et al.. (2024). Stopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study. American Journal of Kidney Diseases. 85(2). 196–204.e1. 2 indexed citations

Sabatini, Silvia, John J. Nolan, Gráinne O’Donoghue, et al.. (2024). Baseline phenotypes with preserved β-cell function and high insulin concentrations have the best improvements in glucose tolerance after weight loss: results from the prospective DEXLIFE and EGIR-RISC studies. Metabolism. 155. 155910–155910. 1 indexed citations

Schwartsmann, Gilberto, et al.. (2024). Does metformin reduce the risk of cancer in obesity and diabetes? A systematic review and meta‐analysis. Diabetes Obesity and Metabolism. 26(5). 1929–1940. 8 indexed citations

McGurnaghan, Stuart J., Luke A. K. Blackbourn, Thomas M. Caparrotta, et al.. (2022). Cohort profile: the Scottish Diabetes Research Network national diabetes cohort – a population-based cohort of people with diabetes in Scotland. BMJ Open. 12(10). e063046–e063046. 15 indexed citations

Boyle, James G., et al.. (2022). Recent developments in adjunct therapies for type 1 diabetes. Expert Opinion on Investigational Drugs. 31(12). 1311–1320. 7 indexed citations

10.

O’Reilly, Joseph, Anita Jeyam, Thomas M. Caparrotta, et al.. (2021). Rising Rates and Widening Socioeconomic Disparities in Diabetic Ketoacidosis in Type 1 Diabetes in Scotland: A Nationwide Retrospective Cohort Observational Study. Diabetes Care. 44(9). 2010–2017. 16 indexed citations

11.

Greenlaw, Nicola, James G. Boyle, Nish Chaturvedi, et al.. (2021). Metformin and carotid intima‐media thickness in never‐smokers with type 1 diabetes: The REMOVAL trial. Diabetes Obesity and Metabolism. 23(6). 1371–1378. 14 indexed citations

12.

Caparrotta, Thomas M., Luke A. K. Blackbourn, Stuart J. McGurnaghan, et al.. (2020). Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium–Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland. Diabetes Care. 43(9). 2034–2041. 14 indexed citations

13.

Kuluski, Kerry, et al.. (2019). Twelve principles to support caregiver engagement in health care systems and health research. SHILAP Revista de lepidopterología. 3 indexed citations

14.

Siméon, S., Ziad A. Massy, Kurt Højlund, et al.. (2018). Renal function markers and insulin sensitivity after 3 years in a healthy cohort, the EGIR-RISC study. BMC Nephrology. 19(1). 124–124. 1 indexed citations

15.

Walker, Jeremy, Helen M. Colhoun, Shona Livingstone, et al.. (2017). Type 2 diabetes, socioeconomic status and life expectancy in Scotland (2012–2014): a population-based observational study. Diabetologia. 61(1). 108–116. 40 indexed citations

16.

Petrie, John R., Nish Chaturvedi, Ian Ford, et al.. (2016). Metformin in adults with type 1 diabetes: D esign and methods of REducing with MetfOrmin V ascular A dverse L esions ( REMOVAL ): A n international multicentre trial. Diabetes Obesity and Metabolism. 19(4). 509–516. 27 indexed citations

17.

Wong, Aaron, D. S. C. Ang, Simon Ogston, et al.. (2012). The Effect of Metformin on Insulin Resistance and Exercise Parameters in Patients with Heart Failure. European Journal of Heart Failure. 14(11). 1303–1310. 74 indexed citations

18.

Ray, Kausik K., R. L. Bennett, John R. Petrie, et al.. (2012). Abstract 15282: Individual Participant Meta Analysis of the Cardiovascular Safety of Taspoglutide Among Individuals with Diabetes. Circulation. 126. 1 indexed citations

19.

Logue, Jennifer, Jeremy Walker, Helen M. Colhoun, et al.. (2011). Do men develop type 2 diabetes at lower body mass indices than women?. Diabetologia. 54(12). 3003–3006. 226 indexed citations

20.

Ang, D. S. C., et al.. (2010). Metformin in insulin resistant LV dysfunction, a double-blind, placebo controlled trial (TAYSIDE trial). Discovery Research Portal (University of Dundee). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact